COMPASS Pathways plc (NASDAQ:CMPS) Receives Average Recommendation of “Buy” from Brokerages

Shares of COMPASS Pathways plc (NASDAQ:CMPS) have been assigned an average recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. Six analysts have rated the stock with a buy recommendation. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $33.60.

CMPS has been the topic of a number of research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $18.00 target price on shares of COMPASS Pathways in a report on Wednesday, January 15th. HC Wainwright decreased their target price on COMPASS Pathways from $120.00 to $60.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. Finally, Maxim Group dropped their target price on shares of COMPASS Pathways from $22.00 to $12.00 and set a “buy” rating for the company in a report on Friday, November 1st.

COMPASS Pathways Stock Up 2.3 %

Shares of NASDAQ CMPS opened at $3.49 on Tuesday. COMPASS Pathways has a 52 week low of $3.16 and a 52 week high of $12.75. The stock’s fifty day moving average is $4.28 and its 200 day moving average is $5.85. The company has a debt-to-equity ratio of 0.15, a quick ratio of 8.91 and a current ratio of 8.91. The stock has a market capitalization of $238.79 million, a P/E ratio of -1.59 and a beta of 2.27.

COMPASS Pathways (NASDAQ:CMPS) last issued its earnings results on Thursday, October 31st. The company reported ($0.56) EPS for the quarter, beating the consensus estimate of ($0.60) by $0.04. During the same quarter last year, the firm earned ($0.67) earnings per share. Sell-side analysts forecast that COMPASS Pathways will post -2.33 earnings per share for the current fiscal year.

Institutional Trading of COMPASS Pathways

Hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC increased its stake in shares of COMPASS Pathways by 1,518.4% in the second quarter. Renaissance Technologies LLC now owns 263,800 shares of the company’s stock valued at $1,593,000 after buying an additional 247,500 shares during the period. Logos Global Management LP increased its position in COMPASS Pathways by 349.3% in the 2nd quarter. Logos Global Management LP now owns 1,159,030 shares of the company’s stock valued at $7,001,000 after acquiring an additional 901,050 shares during the period. Green Alpha Advisors LLC bought a new position in shares of COMPASS Pathways during the third quarter valued at $99,000. Hennion & Walsh Asset Management Inc. lifted its holdings in shares of COMPASS Pathways by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 148,134 shares of the company’s stock worth $933,000 after purchasing an additional 38,145 shares during the period. Finally, Rosalind Advisors Inc. increased its holdings in COMPASS Pathways by 6.5% in the third quarter. Rosalind Advisors Inc. now owns 781,423 shares of the company’s stock valued at $4,923,000 after purchasing an additional 47,423 shares during the period. 46.19% of the stock is owned by institutional investors and hedge funds.

About COMPASS Pathways

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.